Allyx Therapeutics

Another pre-clinical tour de force from our colleagues at Yale School of Medicine demonstrating the effect of our lead drug ALX-001 (BMS-984923) on reversing functional connectivity deficits in an #Alzheimers Disease model. Yale Ventures https://lnkd.in/eZqPqW5x

We are honored to receive this grant from the National Institutes of Health Small Business Innovation Research Program (NIH SBIR) as we continue to advance ALX-001 as a potential first-in-class disease-modifying oral therapy in Alzheimer's disease and Parkinson's disease. https://lnkd.in/eT-4bEEA

Thanks to the Alzheimer's Association® for hosting such an incredible #WalktoEndAlzheimers at Lighthouse Point in New Haven yesterday. We were happy to show our support for the community and remember our goal of helping the patients and families living with this disease. #EndAlz

We are thrilled to announce a significant milestone in our journey to combat #Parkinsons disease, the dosing of our first #PD patient in a Phase 1b 28-day repeat dose clinical study. This marks an important next step in our commitment to developing our innovative therapy, ALX-001, to provide a meaningful impact on the lives of those affected by neurodegenerative diseases. This has been a true collaborative effort with our funding partners at The Michael J. Fox Foundation for Parkinson's Research and the clinical team at the Duke Clinical Research Institute. We also extend our gratitude to the patients, families, and partners who have placed their trust in our mission. Stay tuned for more updates as we continue to advance our research and strive towards a brighter future for Parkinson's disease patients. #Biotech #ClinicalTrials #ParkinsonsDisease #Innovation #Healthcare https://lnkd.in/dq5NQWNd

Another nice feature on our efforts to continue advancing ALX-001 for patients with #Alzheimers Disease. https://lnkd.in/eqNEmmwd

What better timing than during June's #Alzheimer's & Brain Awareness Month than to announce our first #AD patients began treatment with ALX-001, the latest milestone for our team at Allyx Therapeutics. While there has been great progress with anti-amyloid monoclonal therapies and likely an additional commercial treatment option on the way, Alzheimers's will continue to be a major unmet need with patients and families needing more efficacious, safer, and more convenient treatments. This is just the latest milestone in our journey to develop a better and oral treatment for AD. Thanks to all those supporting Allyx Therapeutics in our journey including our investors and grant funders (National Institute on Aging (NIA), Alzheimer's Association®, and The Michael J. Fox Foundation for Parkinson's Research). An additional special thanks to the patients and their families for their participation and enthusiasm. #ENDALZ https://lnkd.in/edPdEkYP

Proud to be recognized by Senator Murphy as April's "Innovator of the Month" for our work in #Alzheimer's and #Parkinson's disease and as an example of the thriving #biotech ecosystem here in Connecticut! https://lnkd.in/gCy9WKNc